 KATY, TX ACCESSWIRE September 13, 2021 Neutra Corp. subsidiary VIVIS has signed a groundbreaking letter of intent LOI with a Houston clinical research company that, if it comes to a successful conclusion, would lead to testing hemp-based cannabinoids to treat COVID-19. Under the LOIs provisions, VIVIS will now determine the feasibility of working with Mercury Clinical Research to start phase 1 clinical trial on CBD efficacies in combating SARS-COVID-2. 